GlassScriptPhysician profile
Mandie E Bagwell
NPI 1720214794
$357.94
in general payments reported to CMS, 2019-2025
10 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.26 · 2024: $59.13 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $123.03 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $55.86 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $29.88 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $24.56 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $24.21 | 2024 | Trintellix |
| Alkermes, INC. | $23.91 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $21.55 | 2025 | Sunosi, Auvelity |
| Lundbeck LLC | $20.02 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.36 | 2024 | Caplyta |
| Neurocrine Biosciences, INC. | $16.56 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandie Bagwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.